Skip to NavigationSkip to content

Johnson & Johnson

Sheri McCoy resigns from Johnson & Johnson

Published on: 10/04/12

Johnson & Johnson has announced that Sheri McCoy, vice chairman of the executive committee, will leave the company on April 18, to join Avon Products as it new chief executive. 

McCoy had been in the running to become the J&J’s new chief executive, after its current head William Weldon announced his decision to step down last year. 

But McCoy lost the race to Alex Gorsky, who will officially take over from Weldon later this month.  

Weldon said: “Sheri has made important contributions across Johnson & Johnson throughout her career. 

European approval for prostate cancer drug Zytiga

Zytiga
Zytiga is an alternative to chemo for late-stage prostate cancer

Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer.

Zytiga (abiraterone acetate) is now licenced as a second-line treatment, in combination with steroid prednisone for metastatic castration-resistant prostate cancer (mCRPC), in men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

The drug is an androgen biosynthesis inhibitor, which blocks the production of testosterone, the hormone responsible for fuelling the cancer.

Xarelto receives FDA approval

Bayer J&J Xarelto (rivaroxaban)

Bayer and Johnson & Johnson’s oral blood thinner Xarelto has been approved in the US for the prevention of deep vein thrombosis after surgery.

Xarelto (rivaroxaban), a Factor Xa inhibitor, is now approved for the prevention of deep vein thrombosis that could lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery in the US, where J&J holds the marketing rights to the drug.

J&J and Vertex's hep C drug Incivek approved by FDA

Vertex's Incivek (telaprevir)
Vertex said its protease inhibitor Incivek (telaprevir) would be launched in the US by the end of the week

The FDA has approved Johnson & Johnson/Vertex’s new oral hepatitis C drug Incivek.

Incivek (telaprevir), a protease inhibitor, is now licenced in the US for use in patients with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

It is approved as a first line treatment, and for previously treated patients who did not achieve a viral cure.

HIV drug Prezista recalled on TBA contamination

Johnson & Johnson has recalled 11,700 bottles of its HIV treatment Prezista after consumer reports of a mouldy smell caused by contamination with 2,4,6 tribromoanisole or TBA.

TBA contamination has been the cause of a number of J&J product recalls in the last couple of years, and has been was traced to plastic bottles and ultimately, to wood treated with a halogenated phenolic preservative which was used to manufacture pallets on which the bott

Top 5 reasons for a Class I product recall

Published on 21/04/11 at 05:25pm
William Weldon
Johnson & Johnson's William Weldon had to explain his company's recall problems to a Congressional investigation

Having to recall a pharmaceutical product because of a major quality defect or safety issue is a heart sinking moment for a drugmaker.

Even where patient safety is not at stake, a recall is an expensive undertaking, not only in direct costs but also damage to reputation and the risk of litigation.

J&J and Merck reach compromise on arthritis drug rights

Arthritis drug Remicade

Johnson & Johnson and Merck & Co have agreed to split the regional rights to arthritis drugs Remicade and Simponi after 18 months of wrangling.

They were in dispute over the rights to Remicade and new arthritis treatment Simponi after Merck merged with J&J’s marketing partner Schering-Plough in November 2009.

J&J reorganises McNeil as recalls keep coming

Johnson & Johnson's Tylenol
The latest recall involves a contaminated product lot of Tylenol

Johnson & Johnson has announced a major reworking of its troubled McNeil Consumer Healthcare unit, just as quality problems force yet another recall of its over-the-counter medicines.

J&J has split the US OTC medicines business into a standalone unit - separate from other consumer products such as skincare and oral health brands - to help achieve closer supervision of its quality and compliance functions. The consumer health division will also be split into four regional areas: North America, Latin America, Europe/Middle East/Africa and Asia-Pacific.

J&J hit by another string of product recalls

There seems to be no end to the quality troubles plaguing Johnson & Johnson, with several more recalls to report, including a pull back of the company's rheumatoid arthritis Simponi in the US and Germany.

The recall could lead to shortages of Simponi (golimumab), according to a European Medicines Agency (EMA). The reason given for the recall is a defect in some of the pen injector devices used to administer the product, which could lead to sub-therapeutic dosing.

Digital Pharma: Pfizer, J&J and Merck withdraw iPhone apps

Pfizer's Les Meningo – Smash Pursuit iPhone app
Pfizer's Les Meningo – Smash Pursuit - one of the iPhone apps no longer on iTunes

Big pharma companies have pulled a number of apps from the iTunes store, but it’s not a sign the industry has fallen out of love with Apple’s iPhone.

Pfizer, Johnson & Johnson and Merck have withdrawn nine apps between them, but all continue to work with the technology.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches